Published in Vaccine Weekly, March 22nd, 2006
Under the terms of the agreement, Avexa will fund the optimization, preclinical and clinical development, and commercialization of any resulting products. MNLpharma will receive milestone payments and royalties. The financial terms were undisclosed.
This agreement follows an initial collaboration between the two companies in 2004, during which the HIV Integrase inhibitors were discovered in MNLpharma's Phytopure library.
Avexa has built...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly